Petropharmaceuticals Group Limited (the “Petropharmaceuticals Group”) informed shareholders and potential investors on 24 January 2024 that its indirect non-wholly owned subsidiary Petrol Innovative Pharmaceutical Co., Ltd. (“Petrol Innovations”) intends to acquire from certain indirect wholly-owned subsidiaries of Petropharmaceuticals Group Bio (Shandong) Biomaterials Proposal for 100% shareholding in Pharmaceutical Co., Ltd. (“Petropharmacy Inc.”). Petropharmacy focuses on the research, development and commercialization of innovative biopharmaceuticals. The main product is Tsuyuli®. Petrol 100's financial data show that for the year ended December 31, 2023, total assets were RMB4,718,695.4 thousand, total liabilities were RMB634,819.8 thousand, company owners' equity was RMB 4,083,875.6 thousand, operating income was 2,663,363.6 thousand and net profit was $859,018.7 thousand. The Group stresses that the financial information is unaudited and reflects only the situation of one of its subsidiaries and does not represent the overall situation of the Group. The terms of the transaction for PDO Innovative and PetroChina are still under negotiation, and the proposed transaction is subject to confirmation after the signing of a formal purchase and sale agreement, so the transaction may not be completed.

Petropharmaceuticals Group Limited (the “Petropharmaceuticals Group”) informed shareholders and potential investors on 24 January 2024 that its indirect non-wholly owned subsidiary Petrol Innovative Pharmaceutical Co., Ltd. (“Petrol Innovations”) intends to acquire from certain indirect wholly-owned subsidiaries of Petropharmaceuticals Group Bio (Shandong) Biomaterials Proposal for 100% shareholding in Pharmaceutical Co., Ltd. (“Petropharmacy Inc.”). Petropharmacy focuses on the research, development and commercialization of innovative biopharmaceuticals. The main product is Tsuyuli®. Petrol 100's financial data show that for the year ended December 31, 2023, total assets were RMB4,718,695.4 thousand, total liabilities were RMB634,819.8 thousand, company owners' equity was RMB 4,083,875.6 thousand, operating income was 2,663,363.6 thousand and net profit was $859,018.7 thousand. The Group stresses that the financial information is unaudited and reflects only the situation of one of its subsidiaries and does not represent the overall situation of the Group. The terms of the transaction for PDO Innovative and PetroChina are still under negotiation, and the proposed transaction is subject to confirmation after the signing of a formal purchase and sale agreement, so the transaction may not be completed.